Juvenile Open Angle Glaucoma

From EyeWiki

Juvenile open-angle glaucoma (JOAG) is a rare subset of glaucoma diagnosed in individuals greater than 3 years old and less than 40 years of age. It is characterized by autosomal dominant inheritance and early age of onset. Compared to adult onset primary open-angle glaucoma (POAG), the juvenile form tends to be rapidly progressive with more severely elevated and fluctuating intraocular pressures (IOPs). In addition, JOAG is less responsive to medications and often requires surgical therapy. Surgical treatment most commonly consists of trabeculectomy although IOP control can be achieved with glaucoma drainage implants and angle surgery as well.

Disease Entity

Juvenile open-angle glaucoma (JOAG)


Juvenile open-angle glaucoma (JOAG) is an uncommon subset of primary open-angle glaucoma (POAG) characterized by autosomal dominant inheritance and early age of onset. Like other forms of glaucoma, JOAG is a condition of optic nerve degeneration manifested by optic nerve head changes and corresponding visual field defects. JOAG is most commonly diagnosed in individuals between 5 and 35 years old and rarely after 40, but age at diagnosis is variable due to the insidious disease course.[1] [2] In a study of 70 JOAG patients, the mean age at diagnosis was 26 ± 9.8 years.[3] JOAG should be distinguished from infantile glaucoma, which develops before the age of 3 and is a clinically distinct disease entity.[4] The estimated prevalence of JOAG ranges from 0.38 to 2 in 100,000 in individuals between 4 and 20 years of age.[1][5] A study from the Dallas Glaucoma Registry estimates that JOAG comprises 4% of childhood glaucomas.[6]


As with primary open angle glaucoma, JOAG is associated with elevations in IOP. It is hypothesized that the increased IOP is due to an abnormal trabecular meshwork causing reduced aqueous outflow.[1] Evidence for this mechanism includes ultra-structural findings of thick compact tissue and extracellular deposits in the trabecular meshwork of individuals with JOAG.[7]

It is possible that vascular perfusion of the optic nerve plays a role as well. A 2020 study used optical coherence tomography angiography (OCT-A) to investigate a correlation between vascular perfusion, RNFL thickness, and best corrected visual acuity (BCVA). They found that RNFL thickness had a strong correlation with peripapillary vessel density and BCVA also had a strong positive correlation with vessel density regardless of RNFL thickness.[8]Vessel densities were much lower in JOAG when compared with POAG.[9]


JOAG is inherited in an autosomal dominant pattern with high penetrance.[2] Of particular importance in the pathogenesis of JOAG is a gene called myocilin (MYOC). Genetic linkage analysis in pedigrees with JOAG identified a locus on chromosome 1q21-31 called GLC1A that was further refined to 1q23-25.[10][11] From this GLC1A locus, the TIGR (trabecular meshwork inducible glucocorticoid response) gene, later renamed myocilin, was isolated.[1] Mutations in myocilin are strongly linked with JOAG, occurring in up to 36% of affected individuals. Disease-causing myocilin mutations are also present in adult onset POAG but at a lesser prevalence of 4%.[12] The lifetime risk of developing glaucoma in MYOC mutation carriers is 60-100%.[13] In addition, patients with strong family histories of glaucoma have an increased likelihood of harboring a disease-causing myocilin mutation.[14]

Myocilin is so named because of its homology to myosin and localization to the ciliary rootlet.[1] Disease-causing mutations in myocilin are thought to increase aqueous outflow resistance as the protein product is expressed on the trabecular meshwork (including trabecular beams and juxtacanalicular connective tissue).[15][16] Myocilin mutations also may have prognostic value as phenotype has been found to correlate with severity of disease.[17] [18] For example, the Gln368Stop mutation is associated with a mild phenotype with later age at diagnosis and lower mean IOP compared to the Tyr437His and Ile477Asn mutations.[1] Another important genetic variation is CYP1B1 (cytochrome P450, family 1, subfamily B, polypeptide 1), which may be a modifier gene that predisposes to JOAG.[7] CYP1B1 has also been linked to congenital glaucoma.[4]

C3 and PZP-like alpha-2-macroglobulin domain-containing protein 8 (CPAMD8) is a protein in corneal endothelial cells and the non-pigmented ciliary epithelium that is involved in the pressure dynamics of the anterior chamber.[19][20] CPAMD8 is implicated in an autosomal recessive anterior segment dysgenesis and has been shown to play a role in some cases of JOAG; in some cohorts, it was the second most common mutation behind MYOC, suggesting that genetic testing for CPAMD8 should be considered for JOAG diagnosis and prognosis.[21] [22] Another study conducted in Australia and New Zealand looked at 327 individuals (622 eyes) with JOAG and found that MYOC was found in 9.5%, CYP1B1 in 3.2%, and CPAMD8, FOXC1, TBK1, COL2Z1, and OPTN were found in less than 1% of patients. Of these participants with JOAG, only around 15% received a molecular diagnosis.[23] [9] Further genetic studies must be completed to identify the genes associated with JOAG and genetic testing panels may be needed in the future for patient-tailored treatment plans.[9]

Risk Factors

  1. Male gender: In a study of 125 eyes, there was a male preponderance of 64%.[24]
  2. Myopia: 87% of JOAG individuals are myopic. In families with JOAG, myopia occurs more frequently in affected individuals.[25]
  3. Severe elevation of IOP: A characteristic feature of JOAG, IOPs generally range over 40 mmHg and even over 50mmHg.[17][18]
  4. African ancestry: There is a higher prevalence of JOAG in this population but not a corresponding higher frequency of MYOC mutations.[13]
  5. Prominent iris processes: This feature may be unrelated to JOAG as it is noted in both affected and unaffected family members in families with JOAG.[25]
  6. MYOC mutation: see Genetics.

Risk factors for visual field (VF) progression:

The projected lifetime risk of perimetric blindness in JOAG is similar to POAG despite the longer duration of disease in JOAG patients.[26]

  1. Long-term IOP fluctuation is associated with faster rates of VF progression.[27]
  2. Higher IOP at the last visit[24]
  3. Family history of glaucoma is weakly associated with VF progression despite similar baseline and last IOPs, number of surgeries, medications, and baseline VF defect.[24]

General Pathology

Ultrastructural findings on electron microscopy showed similar findings to steroid-induced glaucoma, including abnormal extracellular material in a fingerprint-like pattern, resembling basement membrane-like material. A study of 11 trabeculectomy specimens found this material present in the outer corneoscleral and inner cribiform regions of the trabecular meshwork, which thickened the cribiform region to a greater degree compared to eyes with late onset POAG. There is also a significant amount of sheath-derived plaque material in the endothelial layer adjacent to Schlemm’s canal, which is a feature also seen in late onset POAG.[7]



As in POAG a significant proportion of individuals with JOAG are diagnosed when asymptomatic. If symptoms are present, these may include blurred vision, ocular pain from IOP elevation, or decreased visual acuity at later stages.[24] Patients should be asked about family history of glaucoma as well as other history that may indicate a secondary glaucoma.

Physical examination

Physical examination and findings of JOAG are similar to POAG. Exam should include measurement of IOP and central corneal thickness as well as assessment of the anterior chamber angle, optic disc, and visual fields.

  1. IOP: Goldmann Applanation Tonometry (gold standard) or handheld devices such as the Tono-pen may be used. Young individuals may have a larger difference in measurement of IOP between these two methods.[28] See Intraocular Pressure and Tonometry.
  2. Pachymetry: The role of pachymetry in evaluation or management of JOAG has not been formally studied but is currently recommended as part of the work-up for and pre-operative evaluation of JOAG.[4][29]
  3. Anterior chamber angle: In JOAG the anterior segment generally appears normal on gonioscopy. However, with severely elevated pressures, dysgenesis of the angle may be present.[30] High iris insertion or prominent iris processes may also be seen.
  4. Optic disc: Dilated eye exam often reveals bilateral cupping of the optic nerve head at the time of diagnosis.[4] A recent analysis of optic discs using scanning laser ophthalmoscopy concluded that optic discs of JOAG tended to be larger in size compared to adult onset POAG discs including parameters of cup depth, volume, and cup to disc area ratio.[31] This is also true of treated JOAG discs compared to treated primary congenital glaucoma discs. There are no major structural or morphologic differences of the optic nerve head in myocilin mutations versus nonmyocilin glaucoma.[32]
  5. Visual field: Humphrey visual field (HVF) analysis via automated static threshold perimetry is the gold standard. For younger children for whom HVF is not possible, Goldmann visual fields may be used.[4]

Diagnostic procedures

While not necessary for diagnosis, optical coherence tomography (OCT) is helpful for objectively monitoring disease progression in children, especially with the normal increase in axial length that accompanies growth.[33] Humphrey or Goldmann visual field tests may be used to detect early peripheral loss and to monitor progression.

Laboratory test

No laboratory testing is recommended for diagnosis of JOAG.

Differential diagnosis

The differential for JOAG includes other types of open angle glaucoma, late congenital glaucoma, and secondary glaucomas including steroid-induced, traumatic, and inflammatory glaucoma.

The differential for pediatric glaucoma also includes neovascularization of the iris (associated with retinoblastoma presenting with glaucoma), neovascular glaucoma, phakomatoses, juvenile xanthogranuloma, and medulloepithelioma.

JOAG can be distinguished from late congenital glaucoma by the absence of the classic triad of symptoms: buphthalmos, tearing, and photophobia.[4] Exam findings of megalocornea, Descemet’s breaks (Haab’s striae), and anterior segment digenesis seen in congenital glaucoma are also absent in JOAG.[25]


General treatment

Goals of treatment in JOAG include lowering IOP to prevent further degeneration of the optic nerve with serial imaging of the optic nerve head and perimetry to assess disease progression. IOP in JOAG tends to be refractory to maximally tolerated medical therapy and often requires surgical therapy for IOP control.[34]

Medical therapy

In contrast to congenital glaucoma, JOAG is first treated medically followed by adjunctive surgery. It should be noted, however, that medical therapy is often used as a bridge to surgery due to persistently elevated IOPs. In a study of multiple pedigrees genetically linked to the juvenile glaucoma locus on chromosome 1q21-q31, glaucoma filtration surgery was required in 83% of these patients.[25]

Medical therapy is similar to mangagement of POAG and includes carbonic anhydrase inhibitors, prostaglandin analogues (including latanoprost, which is ineffective in congenital glaucoma), beta blockers, and adrenergic agonists. Miotics such as pilocarpine are poorly tolerated due to ciliary spasm and induced myopia. In addition, alpha-agonists should be used with caution in small children due to adverse side effects such as central nervous system depression; for this reason, apraclonidine may be preferable to brimonidine in young children with JOAG.[35]

Selective laser trabeculoplasty (SLT) has resulted in successful IOP reduction in certain patients. In one prospective study published in 2018, 30 JOAG eyes underwent SLT and 43% had significant IOP reduction (>20% reduction) at 12 months without further medication or surgery. They also found that patients without angle dysgenesis were four times more likely to succeed.[36] A follow up study published in 2022 investigated SLT outcomes on patients without angle dysgenesis, which they defined as an absence of Schlemm’s canal and/or presence of a hyperreflective membrane over the trabecular meshwork (TM), as identified on anterior segment optical coherence tomography (ASOCT) before the SLT procedure. Their results show that SLT was 8.3 times more likely to be successful when Schlemm’s canal was visualized on 2 consecutive ASOCT and 21.4 times more likely to be successful when it was visualized on >50% of ASOCTs. Meanwhile, SLT failed to reduce IOP in any eyes with a hyperreflective membrane over the TM.[37] These studies show that SLT can be a reasonable treatment option in JOAG and is much more likely to result in a successful IOP reduction when Schlemm’s canal is visualized on ASOCT and there is not a hyperreflective membrane.


Options for surgical therapy of JOAG include filtration procedures (trabeculectomy), drainage implants, angle procedures (goniotomy, trabeculotomy), and cycloablative procedures.[38]

Trabeculectomy has been the mainstay of surgical therapy for JOAG. Three years postoperatively, IOP control without medications has been reported to occur at rates of 50-87%.[39][40][41] However, filtering surgery in JOAG is generally less successful compared to adult POAG because of a more robust healing response in young eyes. Intraoperative antifibrotics such as mitomycin C (MMC) have been used in an attempt to prevent fibrosis.[41] Although addition of MMC compared to trabeculectomy alone has resulted in lower IOPs, there is an increased risk of adverse effects including hypotony maculopathy and bleb-related infection. This led the authors of a retrospective analysis of 44 eyes to caution against using MMC with an initial trabeculectomy for JOAG.[41]

Glaucoma drainage implants (GDIs) such as the Ahmed glaucoma valve, Molteno implant, and Baerveldt implant are an alternative surgical therapy for JOAG. A GDI may be preferable when significant conjunctival scarring precludes filtration surgery.[42] In a retrospective study of the Ahmed glaucoma valve used for pediatric glaucoma, there was a 100% success rate at 1 year defined as a final IOP between 6-18 mmHg without loss of light perception or reoperation for glaucoma.[43] In a study of 52 eyes with juvenile glaucoma, the Molteno implant resulted in IOP control < 21 with a probability of 0.89 at 1 year.[44]

Micro invasive glaucoma surgery (MIGS) procedures have also been tried for JOAG with some documented success. There have been two documented cases of Xen gel stent (Allergan, Irvine, CA) placement in 2 patients (4 eyes; one 35-year-old pregnant woman and one 48-year-old woman) with 100% success rate of IOP reduction, with elimination of eye drop burden at 2 months and 16 months follow up, respectively.[45] [46] These two cases suggest the possible efficacy of Xen gel stent in JOAG. Another case report published in 2022 discusses the use of a Hydrus stent (Alcon, Forth Worth, TX) in combination with cataract surgery. In this case report of a single patient with JOAG (one eye) with preoperative pressures of 25 mmHg, surgery resulted in decreased IOP that was stable at 14 mmHg at 21 months post operatively.[47] Based on these few reports, MIGS implants may be a viable option for pressure control, but further study on both their safety and efficacy in larger cohorts is needed.

Angle procedures are more commonly used in surgical management of congenital glaucoma and less often for JOAG. However, there are reports of successful angle surgery in JOAG.[29] For example, 360-degree trabeculotomy facilitated by illuminated microcatheter has also been used. In a study of 10 eyes using this technique, there was a 50% reduction in mean IOP. Another retrospective study compared outcomes after gonioscopy-assisted transluminal trabeculotomy (GATT) (n=36) to goniotomy with the Kahook Dual Blade (KDB, New World Medical, Rancho Cucamonga, CA) (n=13) in JOAG eyes. The study found GATT resulted in significant mean IOP reductions of approximately 44% to a mean IOP of 15.4 mmHg, and a mean medication reduction of 2.6 at three months post-operatively. KDB was less successful with a mean IOP reduction of 14% to a mean IOP of 20 mmHg, and a mean medication reduction of 0.7 at three months. Of these patients only 5/36 GATT eyes required a second glaucoma procedure compared to 8/13 KDB eyes. In the GATT group at six months follow up, 90% eliminated at least one drug and 11 GATT patients were drug free. [48]


  1. 1.0 1.1 1.2 1.3 1.4 1.5 Turalba AV, Chen TC. Clinical and genetic characteristics of primary juvenile-onset open-angle glaucoma (JOAG). Semin Ophthalmol. 2008;23(1):19-25.
  2. 2.0 2.1 Wiggs JL, Damji KF, Haines JL, Pericak-Vance MA, Allingham RR. The distinction between juvenile and adult-onset primary open-angle glaucoma. Am J Hum Genet. 1996;58(1):243-244.
  3. Gupta V, Dutta P, OV M, Kapoor KS, Sihota R, Kumar G. Effect of glaucoma on the quality of life of young patients. Invest Ophthalmol Vis Sci. 2011;52(11):8433-8437.
  4. 4.0 4.1 4.2 4.3 4.4 4.5 Babiuch AE, Bradfield YS. Diagnosis and Management of Juvenile Open-Angle Glaucoma. In: Traboulsi, E. UV, eds. Practical Management of Pediatric Ocular Disorders and Strabismus. New York, NY Springer; 2016:471-477.
  5. Aponte EP, Diehl N, Mohney BG. Incidence and clinical characteristics of childhood glaucoma: a population-based study. Arch Ophthalmol. 2010;128(4):478-482.
  6. Fung DS, Roensch MA, Kooner KS, Cavanagh HD, Whitson JT. Epidemiology and characteristics of childhood glaucoma: results from the Dallas Glaucoma Registry. Clin Ophthalmol. 2013;7:1739-1746.
  7. 7.0 7.1 7.2 Furuyoshi N, Furuyoshi M, Futa R, Gottanka J, Lütjen-Drecoll E. Ultrastructural changes in the trabecular meshwork of juvenile glaucoma. Ophthalmologica. 1997;211(3):140-146.
  8. Abdelrahman AM, Eltanamly RM, Elsanabary Z, Hassan LM. Optical coherence tomography angiography in juvenile open angle glaucoma: correlation between structure and perfusion. Int Ophthalmol 2020; 41:883–889.
  9. 9.0 9.1 9.2 Ciociola EC, Klifto MR. Juvenile open angle glaucoma: current diagnosis and management. Curr Opin Ophthalmol. 2022;33(2):97-102. doi:10.1097/ICU.0000000000000813
  10. Sheffield VC, Stone EM, Alward WL, et al. Genetic linkage of familial open angle glaucoma to chromosome 1q21-q31. Nat Genet. 1993;4(1):47-50.
  11. Sunden SL, Alward WL, Nichols BE, et al. Fine mapping of the autosomal dominant juvenile open angle glaucoma (GLC1A) region and evaluation of candidate genes. Genome Res. 1996;6(9):862-869.
  12. Shimizu S, Lichter PR, Johnson AT, et al. Age-dependent prevalence of mutations at the GLC1A locus in primary open-angle glaucoma. Am J Ophthalmol. 2000;130(2):165-177.
  13. 13.0 13.1 Gupta V, Somarajan BI, Gupta S, et al. The inheritance of juvenile onset primary open angle glaucoma. Clin Genet. 2017;92(2):134-142.
  14. Fingert JH. Primary open-angle glaucoma genes. Eye (Lond). 2011;25(5):587-595.
  15. Polansky JR, Fauss DJ, Chen P, et al. Cellular pharmacology and molecular biology of the trabecular meshwork inducible glucocorticoid response gene product. Ophthalmologica. 1997;211(3):126-139.
  16. Quigley HA. The search for glaucoma genes--implications for pathogenesis and disease detection. N Engl J Med. 1998;338(15):1063-1064.
  17. 17.0 17.1 Alward WL, Fingert JH, Coote MA, et al. Clinical features associated with mutations in the chromosome 1 open-angle glaucoma gene (GLC1A). N Engl J Med. 1998;338(15):1022-1027.
  18. 18.0 18.1 Fingert JH, Stone EM, Sheffield VC, Alward WL. Myocilin glaucoma. Surv Ophthalmol. 2002;47(6):547-561.
  19. Janssen SF, Gorgels TG, Ten Brink JB, Jansonius NM, Bergen AA. Gene expression-based comparison of the human secretory neuroepithelia of the brain choroid plexus and the ocular ciliary body: potential implications for glaucoma. Fluids Barriers CNS. 2014;11(1):2. Published 2014 Jan 29. doi:10.1186/2045-8118-11-2
  20. Chen Y, Huang K, Nakatsu MN, Xue Z, Deng SX, Fan G. Identification of novel molecular markers through transcriptomic analysis in human fetal and adult corneal endothelial cells. Hum Mol Genet. 2013;22(7):1271-1279. doi:10.1093/hmg/dds527
  21. Siggs OM, Souzeau E, Taranath DA, et al. Biallelic CPAMD8 Variants Are a Frequent Cause of Childhood and Juvenile Open-Angle Glaucoma. Ophthalmology. 2020;127(6):758-766. doi:10.1016/j.ophtha.2019.12.024
  22. Balikov DA, Jacobson A, Prasov L. Glaucoma Syndromes: Insights into Glaucoma Genetics and Pathogenesis from Monogenic Syndromic Disorders. Genes (Basel). 2021;12(9):1403. Published 2021 Sep 11. doi:10.3390/genes12091403
  23. Knight LSW, Ruddle JB, Taranath DA, et al. Childhood and Early Onset Glaucoma Classification and Genetic Profile in a Large Australasian Disease Registry. Ophthalmology. 2021;128(11):1549-1560. doi:10.1016/j.ophtha.2021.04.016
  24. 24.0 24.1 24.2 24.3 Kwun Y, Lee EJ, Han JC, Kee C. Clinical Characteristics of Juvenile-onset Open Angle Glaucoma. Korean J Ophthalmol. 2016;30(2):127-133.
  25. 25.0 25.1 25.2 25.3 Wiggs JL, Del Bono EA, Schuman JS, Hutchinson BT, Walton DS. Clinical features of five pedigrees genetically linked to the juvenile glaucoma locus on chromosome 1q21-q31. Ophthalmology. 1995;102(12):1782-1789.
  26. Gupta V, Markan A, Somarajan BI, et al. Phenotypic differences between familial versus non-familial Juvenile onset open angle glaucoma patients. Ophthalmic Genet. 2018;39(1):63-67.
  27. Gupta V, Devi K S, Kumar S, et al. Risk of perimetric blindness among juvenile glaucoma patients. Ophthalmic Physiol Opt. 2015;35(2):206-211.
  28. Bradfield YS, Kaminski BM, Repka MX, et al. Comparison of Tono-Pen and Goldmann applanation tonometers for measurement of intraocular pressure in healthy children. J AAPOS. 2012;16(3):242-248.
  29. 29.0 29.1 Stangos AN, Whatham AR, Sunaric-Megevand G. Primary viscocanalostomy for juvenile open-angle glaucoma. Am J Ophthalmol. 2005;140(3):490-496.
  30. Gupta V, Srivastava RM, Rao A, Mittal M, Fingert J. Clinical correlates to the goniodysgensis among juvenile-onset primary open-angle glaucoma patients. Graefes Arch Clin Exp Ophthalmol. 2013;251(6):1571-1576.
  31. Gupta V, James MK, Singh A, et al. Differences in Optic Disc Characteristics of Primary Congenital Glaucoma, Juvenile, and Adult Onset Open Angle Glaucoma Patients. J Glaucoma. 2016;25(3):239-243.
  32. Hewitt AW, Bennett SL, Fingert JH, et al. The optic nerve head in myocilin glaucoma. Invest Ophthalmol Vis Sci. 2007;48(1):238-243.
  33. Ghasia FF, El-Dairi M, Freedman SF, Rajani A, Asrani S. Reproducibility of spectral-domain optical coherence tomography measurements in adult and pediatric glaucoma. J Glaucoma. 2015;24(1):55-63.
  34. Johnson AT, Drack AV, Kwitek AE, Cannon RL, Stone EM, Alward WL. Clinical features and linkage analysis of a family with autosomal dominant juvenile glaucoma. Ophthalmology. 1993;100(4):524-529.
  35. Talbot AW, Russell-Eggitt I. Pharmaceutical management of the childhood glaucomas. Expert Opin Pharmacother. 2000;1(4):697-711.
  36. Gupta V, Ghosh S, Sujeeth M, et al. Selective laser trabeculoplasty for primary open-angle glaucoma patients younger than 40 years. Can J Ophthalmol. 2018;53(1):81-85. doi:10.1016/j.jcjo.2017.07.023
  37. Varshney T, Azmira K, Gupta S, et al. In Vivo Imaging of the Schlemm's Canal and the Response to Selective Laser Trabeculoplasty. Am J Ophthalmol. 2022;234:126-137. doi:10.1016/j.ajo.2021.07.002
  38. Ikeda H, Ishigooka H, Muto T, Tanihara H, Nagata M. Long-term outcome of trabeculotomy for the treatment of developmental glaucoma. Arch Ophthalmol. 2004;122(8):1122-1128.
  39. Gupta V, Ghosh S, Sujeeth M, et al. Selective laser trabeculoplasty for primary open-angle glaucoma patients younger than 40 years. Can J Ophthalmol. 2018;53(1):81-85.
  40. Pathania D, Senthil S, Rao HL, Mandal AK, Garudadari CS. Outcomes of trabeculectomy in juvenile open angle glaucoma. Indian J Ophthalmol. 2014;62(2):224-228.
  41. 41.0 41.1 41.2 Tsai JC, Chang HW, Kao CN, Lai IC, Teng MC. Trabeculectomy with mitomycin C versus trabeculectomy alone for juvenile primary open-angle glaucoma. Ophthalmologica. 2003;217(1):24-30.
  42. Ishida K, Mandal AK, Netland PA. Glaucoma drainage implants in pediatric patients. Ophthalmol Clin North Am. 2005;18(3):431-442, vii.
  43. Balekudaru S, Vadalkar J, George R, Vijaya L. The use of Ahmed glaucoma valve in the management of pediatric glaucoma. J AAPOS. 2014;18(4):351-356.
  44. Ah-Chan JJ, Molteno AC, Bevin TH, Herbison P. Otago Glaucoma Surgery Outcome Study: follow-up of young patients who underwent Molteno implant surgery. Ophthalmology. 2005;112(12):2137-2142.
  45. Klug E, Solá-Del Valle D. Bilateral XEN Gel Stent Implantation in Juvenile-Onset Open-Angle Glaucoma. Case Rep Ophthalmol. 2020;11(2):336-341. Published 2020 Jul 14. doi:10.1159/000508391
  46. Zehavi-Dorin T, Heinecke E, Nadkarni S, Green C, Chen C, Kong YXG. Bilateral consecutive Xen gel stent surgery during pregnancy for uncontrolled early-onset primary open angle glaucoma. Am J Ophthalmol Case Rep. 2019;15:100510. Published 2019 Jul 11. doi:10.1016/j.ajoc.2019.100510
  47. Oseni J, Laroche D. Cataract surgery and Hydrus stent implantation in juvenile open-angle glaucoma: A case report [published online ahead of print, 2022 Sep 24]. J Natl Med Assoc. 2022;S0027-9684(22)00155-9. Doi:10.1016/j.jnma.2022.09.004
  48. Qiao Y, Tan C, Chen X, Sun X, Chen J. Gonioscopy-assisted transluminal trabeculotomy versus goniotomy with Kahook dual blade in patients with uncontrolled juvenile open-angle glaucoma: a retrospective study. BMC Ophthalmol. 2021;21(1):395. Published 2021 Nov 16. doi:10.1186/s12886-021-02159-z
  1. Lim ME, Dao JB, Freedman SF. 360-Degree Trabeculotomy for Medically Refractory Glaucoma Following Cataract Surgery and Juvenile Open-Angle Glaucoma. Am J Ophthalmol. 2017;175:1-7.
  2. Leung CK, Woo J, Tsang MK, Tse KK. Structural and functional recovery in juvenile open angle glaucoma after trabeculectomy. Eye (Lond). 2006;20(1):132-134.
  3. Ely AL, El-Dairi MA, Freedman SF. Cupping reversal in pediatric glaucoma--evaluation of the retinal nerve fiber layer and visual field. Am J Ophthalmol. 2014;158(5):905-915.
The Academy uses cookies to analyze performance and provide relevant personalized content to users of our website.